◀ Back to EPHB2

EPHB2 — PDGFRB

Text-mined interactions from Literome

Mondorf et al., FEBS Lett 2000 : Ang II induced activation of ERK1/2 via the AT(1) receptor, and this response was blocked by the PDGFR-selective tyrosine kinase inhibitor AG1295, but not by AG1478, an EGFR-selective tyrosine kinase inhibitor, indicating participation of the PDGFR , but not of the EGFR in Ang II-induced ERK1/2 activation
Rosenfeldt et al., FASEB J 2001 : In contrast, tyrosine phosphorylation of the PDGFR and activation of extracellular signal regulated kinase ( ERK1/2 ), important for growth and survival, were unaltered
Allard et al., American journal of physiology. Renal physiology 2007 (Albuminuria...) : The early phase of diabetes was found to be associated with an increase in glomerular expression of IGF1-R, PDGF-R , and TGF-beta-RII and activation of IRS1, Erk 1/2, and Smad 2/3
Ammoun et al., Cancer Res 2008 (MAP Kinase Signaling System...) : Using specific inhibitors, we discovered that ERK1/2 activation involves the integrin/focal adhesion kinase/Src/Ras signaling cascades and PDGFRbeta mediated ERK1/2 activation is triggered through the phosphatidylinositol 3-kinase/protein kinase C/Src/c-Raf pathway ... The PDGFR and c-Raf inhibitor sorafenib ( BAY 43-9006 ; Bayer Pharmaceuticals ), currently approved for treatment of advanced renal cell cancer, inhibits both basal and PDGFRbeta mediated ERK1/2 and AKT activity and decreases cell proliferation in human schwannoma cells, suggesting that this drug constitutes a promising tool to treat schwannomas
Herrlich et al., Proc Natl Acad Sci U S A 1998 : The cross-talk appears to be cell type-specific : In L cells that lack EGFR, lysophosphatidic acid induced Shc and ERK activation is prevented completely by specific inhibition of PDGFR , whereas in COS-7 cells expressing only EGFR, the pathway via EGFR is chosen